Compare Stocks: MGX, MRNA, ADCT, and ALXO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.72 +7.9%	$1.17	$0.78 ▼ $4.98	$220.87M	1.86	1.65 million shs	3.13 million shs
ALXO ALX Oncology	$1.25 +5.9%	$1.78	$1.05 ▼ $2.66	$172.85M	0.47	1.42 million shs	1.22 million shs
MGX Metagenomi	$1.00 +0.7%	$1.16	$0.96 ▼ $3.95	$37.78M	0.69	142,733 shs	146,836 shs
MRNA Moderna	$225.00 +14.2%	$140.07	$22.28 ▼ $225.00	$89.83B	1.09	16.98 million shs	28.85 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+52.44%	+55.20%	+33.46%	-62.22%
ALXO ALX Oncology	0.00%	+2.46%	-34.21%	-41.31%	-36.55%
MGX Metagenomi	0.00%	-1.96%	-13.79%	-21.26%	-68.65%
MRNA Moderna	0.00%	+18.41%	+64.69%	+229.57%	+705.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.72 +7.9%	$1.17	$0.78 ▼ $4.98	$220.87M	1.86	1.65 million shs	3.13 million shs
ALXO ALX Oncology	$1.25 +5.9%	$1.78	$1.05 ▼ $2.66	$172.85M	0.47	1.42 million shs	1.22 million shs
MGX Metagenomi	$1.00 +0.7%	$1.16	$0.96 ▼ $3.95	$37.78M	0.69	142,733 shs	146,836 shs
MRNA Moderna	$225.00 +14.2%	$140.07	$22.28 ▼ $225.00	$89.83B	1.09	16.98 million shs	28.85 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	+52.44%	+55.20%	+33.46%	-62.22%
ALXO ALX Oncology	0.00%	+2.46%	-34.21%	-41.31%	-36.55%
MGX Metagenomi	0.00%	-1.96%	-13.79%	-21.26%	-68.65%
MRNA Moderna	0.00%	+18.41%	+64.69%	+229.57%	+705.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	191.55% Upside
ALXO ALX Oncology	2.67	Moderate Buy	$4.60	268.00% Upside
MGX Metagenomi	2.75	Moderate Buy	$6.00	500.00% Upside
MRNA Moderna	2.08	Hold	$78.17	-65.26% Downside

Current Analyst Ratings Breakdown

Latest MGX, MRNA, ADCT, and ALXO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$89.00 ➝ $95.00
9/30/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$60.00 ➝ $80.00
9/25/2026	MRNA Moderna	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/23/2026	MRNA Moderna	Singular Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/22/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/22/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/17/2026	ALXO ALX Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	MRNA Moderna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	2.69	N/A	N/A	($1.50) per share	-1.14
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$0.48 per share	N/A
MGX Metagenomi	$25.21M	1.50	N/A	N/A	$4.22 per share	0.24
MRNA Moderna	$1.94B	46.21	N/A	N/A	$22.14 per share	10.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
ALXO ALX Oncology	-$101.69M	-$1.13	N/A	N/A	N/A	N/A	-90.30%	-67.28%	11/6/2026 (Estimated)
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)

Latest MGX, MRNA, ADCT, and ALXO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	ALXO ALX Oncology	-$0.15	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	MRNA Moderna	-$1.10	N/A	N/A	N/A	$892.40 million	N/A
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
8/6/2026	Q2 2026	ALXO ALX Oncology	-$0.1429	-$0.13	+$0.0129	-$0.13	N/A	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
ALXO ALX Oncology	0.07	9.71	9.71
MGX Metagenomi	N/A	4.50	4.50
MRNA Moderna	0.09	2.29	2.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
ALXO ALX Oncology	97.97%
MGX Metagenomi	N/A
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
ALXO ALX Oncology	12.40%
MGX Metagenomi	12.50%
MRNA Moderna	10.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
ALXO ALX Oncology	48	138.28 million	121.13 million	Optionable
MGX Metagenomi	113	37.78 million	33.06 million	N/A
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable

MGX, MRNA, ADCT, and ALXO Headlines

Recent News About These Companies

Moderna Now Trades 61% Above Wall Street's Average Price Target. Should You Sell?

October 10 at 6:15 PM | fool.com

Moderna gains 14% to set fresh 52-week high

October 10 at 4:16 PM | seekingalpha.com

Promising Healthcare Stocks To Follow Today - October 10th

October 10 at 1:04 PM | marketbeat.com

Top Biotech Stocks To Watch Now - October 10th

October 10 at 12:00 PM | marketbeat.com

Moderna (MRNA) Stock Hits 52-Week High After Cancer Vaccine Initiative Report

October 10 at 11:14 AM | coincentral.comC

Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative

October 10 at 6:14 AM | finance.yahoo.com

11,652 Shares of Moderna, Inc. $MRNA Acquired by Gallagher Capital Advisors LLC

October 10 at 4:31 AM | marketbeat.com

Why Moderna Stock Surged Today

October 9 at 7:47 PM | fool.com

Moderna stock skyrockets on reports of US cancer vaccine initiative

October 9 at 7:22 PM | msn.com

MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push

October 9 at 7:22 PM | finance.yahoo.com

The science and politics of the new mRNA flu vaccine

October 9 at 2:20 PM | sciencefriday.comS

Market Chatter: Moderna, Other Vaccine Developer Stocks Rise as NIH Plans to Expedite Cancer Vaccines

October 9 at 2:20 PM | finance.yahoo.com

Moderna stock fires past 52-week high: what's behind Friday's rally?

October 9 at 2:20 PM | msn.com

Moderna stock jumps on planned national cancer vaccine effort

October 9 at 2:20 PM | finance.yahoo.com

Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies

October 9 at 1:59 PM | 247wallst.com

Moderna, Inc. $MRNA Shares Sold by Douglas Lane & Associates LLC

October 9 at 1:08 PM | marketbeat.com

Top Healthcare Stocks To Research - October 9th

October 9 at 1:01 PM | marketbeat.com

Biotech Stocks To Follow Today - October 9th

October 9 at 12:01 PM | marketbeat.com

Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up

October 9 at 11:48 AM | 247wallst.com

Moderna (NASDAQ:MRNA) Shares Up 8.3% - Here's Why

October 9 at 11:39 AM | marketbeat.com

Moderna's Factory Floor Becomes the Real Battleground After 555% Run

October 9 at 7:50 AM | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX, MRNA, ADCT, and ALXO Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.72 +0.13 (+7.86%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$1.71 0.00 (-0.17%)

As of 10/9/2026 08:00 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ALX Oncology NASDAQ:ALXO

$1.25 +0.07 (+5.93%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.20 -0.05 (-4.00%)

As of 10/9/2026 07:30 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Metagenomi NASDAQ:MGX

$1.00 +0.01 (+0.68%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.00 (+0.10%)

As of 10/9/2026 07:37 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Moderna NASDAQ:MRNA

$225.00 +28.00 (+14.21%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$225.45 +0.45 (+0.20%)

As of 10/9/2026 08:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGX, MRNA, ADCT, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGX, MRNA, ADCT, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGX, MRNA, ADCT, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX, MRNA, ADCT, and ALXO Company Descriptions

ADC Therapeutics NYSE:ADCT

ALX Oncology NASDAQ:ALXO

Metagenomi NASDAQ:MGX

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGX, MRNA, ADCT, and ALXO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGX, MRNA, ADCT, and ALXO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGX, MRNA, ADCT, and ALXO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX, MRNA, ADCT, and ALXO Company Descriptions

ADC Therapeutics NYSE:ADCT

ALX Oncology NASDAQ:ALXO

Metagenomi NASDAQ:MGX

Moderna NASDAQ:MRNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools